Company intelligence / Profile preview

Verseon

Fremont, California, United Statesverseon.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Verseon's pipeline includes at least 16 candidates across 8 programs targeting cancer and cardiometabolic diseases. VE‑1902, a thrombin inhibitor for cardiovascular disorders, has reached Phase 1 trials. Oncology candidates are in preclinical or optimization stages. The company claims its proprietary platform enables the discovery of novel drugs that cannot be found by other current methods.

Therapeutic areas: OncologyCardiovascular
Modalities: Small molecules
Industry: Biotech

Drug pipeline

10 assets

VE-1902

Preclinical

9 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Verseon.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Verseon.

Explore the full profile